Vietnam homegrown COVID vaccine heads for full approval by year-end

HANOI -- Vietnam's domestically developed coronavirus vaccine candidate has begun Phase 3 clinical trials, with the country hoping to package doses for market by the end of the year.

Nanocovax, developed by startup Nanogen Pharmaceutical Biotechnology in collaboration with Vietnam Military Medical University, started the final trials on Thursday, the company said. About 13,000 people will participate in the trials, and the results will be compiled by September, Nanogen said.